Press Release

India Rifampicin Market to Grow with a CAGR of 5.10% through 2030

High Tuberculosis (TB) Burden and Strong Demand for Fixed-Dose Combination (FDC) Therapies is expected to drive the India Rifampicin Market growth in the forecast period, 2026-2030

 

According to TechSci Research report, “India Rifampicin Market – By Region, Competition, Forecast & Opportunities, 2030F”, the India Rifampicin Market stood at USD 540.24 Million in 2024 and is anticipated to grow with a CAGR of 5.10% in the forecast period, 2026-2030.

India is a global leader in the manufacturing of active pharmaceutical ingredients (APIs), with the country's pharmaceutical industry significantly expanding its rifampicin production capabilities. Prominent Indian companies such as Lupin, Macleods Pharmaceuticals, and Cadila Pharmaceuticals are making substantial investments in state-of-the-art manufacturing facilities to enhance production capacity and ensure a reliable supply. Furthermore, the growing export demand from high tuberculosis (TB)-burden countries in Africa and Southeast Asia positions Indian manufacturers to effectively tap into lucrative international markets.

In terms of government support, India has introduced several initiatives, including the Production-Linked Incentive (PLI) Scheme for Pharmaceuticals, aimed at reducing reliance on imported APIs and strengthening domestic manufacturing. This aligns with the country’s broader objective of achieving self-sufficiency in essential medicines, including rifampicin. Price controls and subsidies under the National List of Essential Medicines (NLEM) further facilitate affordability, driving market expansion.

Beyond TB, rifampicin is also used in the treatment of leprosy, Legionnaire’s disease, and prosthetic joint infections, broadening its potential market. Additionally, the rise in drug-resistant bacterial infections has led to increased off-label use in hospital settings, creating additional avenues for demand growth.

                                                                                             

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "India Rifampicin Market

 

The India Rifampicin Market is segmented into source, form, route of administration, application, end user, regional distribution, and company.

Based on its distribution channel, the offline distribution segment has emerged as the predominant market leader, Rifampicin is primarily prescribed for TB treatment, which is usually managed in clinical settings. Public and private healthcare institutions are the main points of access for TB drugs. Hospitals, particularly those under government-run programs like the Revised National Tuberculosis Control Program (RNTCP), are crucial in ensuring that patients receive the right treatment. These facilities account for a large volume of rifampicin prescriptions and distribution, making the offline channel the dominant mode for delivering the drug to patients.

Government programs aimed at eradicating TB, such as the National TB Elimination Program (NTEP), play a significant role in the distribution of rifampicin. These programs focus on offline distribution through a network of healthcare centers, often in rural and underserved areas, where access to online platforms is limited. Rifampicin is made available free of charge or at subsidized rates, primarily through offline channels. In India, pharmacies remain a trusted source for acquiring prescription medications like rifampicin. Many patients, particularly in semi-urban and rural areas, still prefer visiting physical pharmacies for prescriptions, especially when it involves ongoing, long-term treatments like TB management. The widespread presence of local drugstores facilitates easy access to rifampicin.

 

Major companies operating in India Rifampicin Market are:

  • Indian Drugs and Pharmaceuticals Ltd.
  • Cadila Pharmaceuticals Limited
  • Macleods Pharmaceuticals Ltd.
  • Lupin Limited
  • Concept Pharmaceuticals Ltd
  • Novartis India
  • Zydus Group
  • Themis Medicare Ltd
  • GSK plc.
  • Taurus Laboratories Pvt. Ltd

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The India rifampicin market is poised for continued growth, driven by the country’s high tuberculosis burden, ongoing government initiatives, and advancements in pharmaceutical manufacturing. While the offline distribution channel remains dominant, the rise of online platforms and digital healthcare solutions presents emerging opportunities for market expansion. Indian pharmaceutical companies, supported by government incentives and global export demand, are well-positioned to strengthen their production capabilities and expand their market reach. As the healthcare landscape evolves, particularly with increasing focus on drug-resistant TB, the demand for rifampicin is expected to remain robust, ensuring that India plays a critical role in the global TB eradication efforts.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

India Rifampicin Market, By Source (In-house, Contract Manufacturing Organizations), By Form (Tablet, Capsule, Injection), By Route of Administration (Oral, Intravenous), By Distribution Channel (Online, Offline), By Application (Tuberculosis, Leprosy, Legionnaire's Disease, Others), By End User (Adult, Paediatric), By Region, Competition, Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of India Rifampicin Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in India Rifampicin Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News